Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M N Raber

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary originR Lenzi, M N Raber, P Frost, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsN Touroutoglou, D Gravel, M N Raber, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acidJ L Abbruzzese, R Amato, S Schmidt, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid tumorsR L Theriault, I A Cohen, L Esparza, et al.
Cytometry|July 1, 1982
Ploidy, proliferative activity and estrogen receptor content in human breast cancerM N Raber, B Barlogie, J Latreille, et al.
Cancer Treatment Reports|April 1, 1987
Phase I trial of caracemide using bolus and infusion schedulesM N Raber, F Adams, J Kavanagh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Analysis of a diagnostic strategy for patients with suspected tumors of unknown originJ L Abbruzzese, M C Abbruzzese, R Lenzi, et al.
Journal of the National Cancer Institute|April 3, 1996
Are time or intensity factors important to the definition of metastases of unknown origin?J L Abbruzzese, M C Abbruzzese, R Lenzi, et al.
Cancer Treatment Reviews|October 1, 1993
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere)R Pazdur, A P Kudelka, J J Kavanagh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinomaK R Hess, M C Abbruzzese, R Lenzi, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary originR Lenzi, M N Raber, P Frost, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsN Touroutoglou, D Gravel, M N Raber, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acidJ L Abbruzzese, R Amato, S Schmidt, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid tumorsR L Theriault, I A Cohen, L Esparza, et al.
Cytometry|July 1, 1982
Ploidy, proliferative activity and estrogen receptor content in human breast cancerM N Raber, B Barlogie, J Latreille, et al.
Cancer Treatment Reports|April 1, 1987
Phase I trial of caracemide using bolus and infusion schedulesM N Raber, F Adams, J Kavanagh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Analysis of a diagnostic strategy for patients with suspected tumors of unknown originJ L Abbruzzese, M C Abbruzzese, R Lenzi, et al.
Journal of the National Cancer Institute|April 3, 1996
Are time or intensity factors important to the definition of metastases of unknown origin?J L Abbruzzese, M C Abbruzzese, R Lenzi, et al.
Cancer Treatment Reviews|October 1, 1993
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere)R Pazdur, A P Kudelka, J J Kavanagh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinomaK R Hess, M C Abbruzzese, R Lenzi, et al.
Pageof 6